SEC Tracker
Get the app

Biomerica BMRA

Biomerica FY 2025: revenue $5.3M, down 2%; diluted EPS −$2.16

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Biomerica reported for the year ended May 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$5.3M−2% from $5.4M in FY 202410-K income statement, on EDGAR
  2. Net income−$5.0MAgainst −$6.0M in FY 202410-K income statement, on EDGAR
  3. Diluted EPS−$2.16Against −$0.36 in FY 202410-K income statement, on EDGAR
  4. Cash and cash equivalents$2.4M−42% from $4.2M in FY 202410-K balance sheet, on EDGAR
  5. Cash from operations−$3.8MAgainst −$5.4M in FY 202410-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Biomerica files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  4. Vyome Holdings HIND public float $6M, Jun 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025